The Application of Botulinum Toxin in the Prophylactic Treatment of Migraine
By:
References
- Raciti L, Raciti G, Militi D, Casella C, Calabrò RS. Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions. J Integr Neurosci. 2022 Aug 10;21(5):141. doi: 10.31083/j.jin2105141. PMID: 36137961.
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. PMID: 29368949.
- Kępczyńska K, Domitrz I. Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches. Toxins (Basel). 2022 Sep 5;14(9):619. doi: 10.3390/toxins14090619. PMID: 36136557; PMCID: PMC9501363.
- Loredana Raciti, Gianfranco Raciti, David Militi, Carmela Casella, Rocco Salvatore Calabrò. Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions. J. Integr. Neurosci. 2022, 21(5), 141.
- Burstein, R., Blumenfeld, A.M., Silberstein, S.D., Manack Adams, A. and Brin, M.F. (2020), Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. Headache: The Journal of Head and Face Pain, 60: 1259-1272.
- Stovner LJ, Hagen K, Tronvik E, Bruvik Gravdahl G, Burstein R, Dodick DW. FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine. Cephalalgia. 2022;42(7):590-597.
- Pijpers JA, Kies DA, Louter MA, van Zwet EW, Ferrari MD, Terwindt GM. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain. 2019 May 1;142(5):1203-1214. doi: 10.1093/brain/awz052. PMID: 30982843; PMCID: PMC6511115.
- Aurora SK, Zwycięzca P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC. OnabotulinumtoxinA do leczenia przewlekłej migreny: zbiorcze analizy 56-tygodniowego programu klinicznego PREEMPT. Ból głowy. 2011 Oct;51(9):1358-73. Doi: 10.1111/j.1526-4610.2011.01990.x. EPUB 2011 29 sierpnia. PMID: 21883197.
- Wilderman I, Tallarigo D, Pugacheva-Zingerman O. A Qualitative Study to Explore Patient Perspectives of Prophylactic Treatment with OnabotulinumtoxinA for Chronic Migraine. Pain Ther. 2021 Dec;10(2):1523-1536. doi: 10.1007/s40122-021-00316-2. Epub 2021 Sep 14. PMID: 34523107; PMCID: PMC8586057.
- Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A, Rothrock JF. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. J Prim Care Community Health. 2020 Jan-Dec;11:2150132720959936. doi: 10.1177/2150132720959936. PMID: 32985341; PMCID: PMC7536482.
- Winner PK, Blumenfeld AM, Eross EJ, Orejudos AC, Mirjah DL, Adams AM, Brin MF. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study. Drug Saf. 2019 Aug;42(8):1013-1024. doi: 10.1007/s40264-019-00824-3. PMID: 31102144; PMCID: PMC6647876.
- Shen B, Wang L. Impact of the botulinum-A toxin on prevention of adult migraine disorders. J Integr Neurosci. 2020 Mar 30;19(1):201-208. doi: 10.31083/j.jin.2020.01.1240. PMID: 32259898
- Herd, Clare P., et al. “Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine.” BMJ open 9.7 (2019): e027953.
- Raciti L, Raciti G, Militi D, Casella C, Calabrò RS. Przewlekła migrena: przegląd narracyjny na temat stosowania toksyny botulinowej ze wskazaniami klinicznymi i przyszłymi wskazówkami. J Integr Neurosci. 2022 Sie 10;21(5):141. Doi: 10.31083/j.jin2105141. PMID: 36137961.
- Blumenfeld AM, Kaur G, Mahajan A, Shukla H, Sommer K, Tung A, Knievel KL. Effectiveness and Safety of Chronic Migraine Preventive Treatments: A Systematic Literature Review. Pain Ther. 2023 Feb;12(1):251-274. doi: 10.1007/s40122-022-00452-3. Epub 2022 Nov 22. PMID: 36417165; PMCID: PMC9845441.
- Görür K, Gür H, İsmi O, Özcan C, Vayisoğlu Y. The effectiveness of propranolol, flunarizine, amitriptyline and botulinum toxin in vestibular migraine complaints and prophylaxis: a non-randomized controlled study. Braz J Otorhinolaryngol. 2022 Nov-Dec;88(6):975-981. doi: 10.1016/j.bjorl.2021.02.005. Epub 2021 Mar 7. PMID: 33722518; PMCID: PMC9615515.
- Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM; FORWARD Study investigative group. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. Headache. 2019 Nov;59(10):1700-1713. doi: 10.1111/head.13653. Epub 2019 Sep 26. PMID: 31559634; PMCID: PMC6899480.
- Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A, Rothrock JF. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. J Prim Care Community Health. 2020 Jan-Dec;11:2150132720959936. doi: 10.1177/2150132720959936. PMID: 32985341; PMCID: PMC7536482.
- Hansson-Hedblom A, Axelsson I, Jacobson L, Tedroff J, Borgström F. Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. J Headache Pain. 2020 Aug 12;21(1):99. doi: 10.1186/s10194-020-01162-x. PMID: 32787820; PMCID: PMC7424684.
- Kollewe K, Gaul C, Gendolla A, Sommer K. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. J Headache Pain. 2021 Jun 2;22(1):50. doi: 10.1186/s10194-021-01260-4. PMID: 34078259; PMCID: PMC8173963.
- Wong HT, Khalil M, Ahmed F. OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients. J Headache Pain. 2020 Oct 29;21(1):129. doi: 10.1186/s10194-020-01196-1. PMID: 33121432; PMCID: PMC7599093.
Language: English
Page range: 63 - 72
Submitted on: Aug 14, 2023
Accepted on: Sep 13, 2023
Published on: Oct 12, 2024
Published by: Polish Hyperbaric Medicine and Technology Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2024 Dominika Kuźmiuk, Paulina Pawłowska, Aleksandra Skorupa, Natalia Marko, Barbara Nieradko-Iwanicka, Małgorzata Witkowska-Zimny, published by Polish Hyperbaric Medicine and Technology Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.